Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics (SMMT)
NASDAQ:SMMT
SMMT Stock Chart & Stats
$17.04
$0.42(2.31%)
At close: 4:00 PM EST
$17.04
$0.42(2.31%)
Day’s Range― - ―
52-Week Range$15.55 - $36.91
Previous CloseN/A
Volume1.23M
Average Volume (3M)2.34M
Market Cap
$12.66B
Enterprise Value$15.13B
Total Cash (Recent Filing)$238.88M
Total Debt (Recent Filing)$5.43M
Price to Earnings (P/E)―
Beta2.49
Next Earnings
Mar 12, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding744,442,570
10 Day Avg. Volume2,571,065
30 Day Avg. Volume2,341,078
Financial Highlights & Ratios
PEG Ratio0.84
Price to Book (P/B)32.99
Price to Sales (P/S)0.00
P/FCF Ratio-90.17
Enterprise Value/Market Cap1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.01K
Enterprise Value/Ebitda-16.41
Forecast
1Y Price Target
$42.49Price Target Upside149.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe company is advancing its Phase III trials, which indicates progress in their development pipeline.
Safety ProfileSafety looked substantially better than PD-1 + VEGF combo, with a clean safety profile and lower risk of bleeding supporting potential combo benefits in the long run.
Trial OutcomesIvonescimab reduced the risk of progression or death by 49% compared to KEYTRUDA, marking it as the only bispecific to outperform the PD-1 benchmark head-to-head.
Bears Say
Approval ProbabilityThere is a reduction in the NSCLC probability of approval from 85% to 80% and an increase in operational expenses to reflect a larger Phase 3 footprint.
Capital RequirementsThere is a need to raise substantial capital, with the financial runway appearing to be approximately two quarters.
Investor FocusInvestors are focused solely on OS outcomes, overlooking the fact that ivonescimab has delivered two unambiguous PFS wins across NSCLC settings.
Summit Therapeutics News
SMMT FAQ
What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $15.55 and its highest was $36.91 in the past 12 months.
What is Summit Therapeutics’s market cap?
Summit Therapeutics’s market cap is $12.66B.
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 83 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on Oct 20, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.14.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -0.24.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 744,442,570 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -4.526%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Currently, no hedge funds are holding shares in SMMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Summit Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.49 (149.35% Upside)
$42.49 (149.35% Upside)
Blogger Sentiment
Bullish
SMMT Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 7.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $11.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.40%
12-Months-Change
Fundamentals
Return on Equity
-292.49%
Trailing 12-Months
Asset Growth
-47.95%
Trailing 12-Months
Company Description
Summit Therapeutics
Summit Therapeutics (SMMT) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibiotics to combat infections caused by multi-drug resistant bacteria. The company operates in the healthcare sector, with a primary focus on developing new treatments for infectious diseases through its innovative pipeline of antibiotic candidates.
SMMT Company Deck
SMMT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong clinical trial results and expansion plans with multiple Phase III trials, indicating significant progress and potential for ivonescimab in various cancer treatments. However, financial concerns and increased expenses were noted as challenges.View all SMMT earnings summariesSMMT Stock 12 Month Forecast
Average Price Target
$42.49
▲(149.35% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---